BRCA1 and Lynch syndrome: In contrast, clinical genetic testing for specific diseases (which in 2020 only included “High risk cancer testing for example, BRCA1/2 or Lynch Syndrome”) has increased from 36% to 55% and use has increased from 5% to 16%.